Atrium Therapeutics financials
$8.420.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $19.6M | $860.0K | $12.5M | $3.8M | $1.6M | $3.0M | $2.3M | $2.0M | $3.5M | $2.2M | $2.8M |
| Gross profit | $3.0M | $19.6M | $860.0K | $12.5M | $3.8M | $1.6M | $3.0M | $2.3M | $2.0M | $3.5M | $2.2M | $2.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$22.6M | -$17.3M | -$254.5M | -$188.8M | -$171.1M | -$131.5M | -$121.0M | -$98.1M | -$82.6M | -$77.2M | -$66.7M | -$58.6M |
| Net income | -$20.2M | -$16.6M | -$237.1M | -$174.4M | -$157.3M | -$115.8M | -$102.3M | -$80.4M | -$70.8M | -$68.9M | -$60.4M | -$52.4M |
| Net margin | −672.0% | −84.7% | −27569.9% | −1398.3% | −4089.3% | −7360.0% | −3439.5% | −3441.7% | −3461.8% | −1943.4% | −2756.2% | −1858.0% |
| Diluted EPS | $-1.18 | $-0.97 | $-1.54 | $-1.27 | $-1.21 | $-0.90 | $-0.79 | $-0.65 | $-0.65 | $-0.79 | $-0.79 | $-0.71 |
| EBITDA | -$22.3M | -$17.1M | -$253.0M | -$187.8M | -$170.3M | -$130.7M | -$120.3M | -$97.4M | -$81.9M | -$76.5M | -$66.7M | -$58.1M |
| Operating cash flow | -$3.9M | -$31.1M | -$169.8M | -$156.2M | -$199.7M | -$124.8M | -$99.9M | -$65.6M | -$65.0M | -$70.4M | $16.5M | -$36.8M |
| Free cash flow | -$4.0M | -$33.2M | -$175.3M | -$156.9M | -$203.0M | -$128.6M | -$103.8M | -$67.3M | -$65.5M | -$71.3M | $15.6M | -$37.7M |
| Diluted shares | 17.1M | 17.1M | 154.1M | 137.9M | 129.6M | 129.2M | 128.8M | 123.4M | 106.9M | 87.2M | 76.1M | 74.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $72.3M | $267.8M | $382.5M | $350.2M | $243.9M | $254.2M |
| Short-term investments | $191.6M | $0.00 | $1.31B | $1.53B | $939.2M | $1.13B |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $280.5M | $292.4M | $1.96B | $2.13B | $1.37B | $1.46B |
| Total liabilities | $65.9M | $58.3M | $269.4M | $247.9M | $176.3M | $130.4M |
| Shareholders' equity | $214.6M | $234.1M | $1.69B | $1.89B | $1.19B | $1.33B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology